Cambridge Cognition Holdings (LSE:COG) 5-Year EBITDA Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:COG Cambridge Cognition Holdings PLC LSE:COG
47 GF Score
Price £0.33
GF Value £0.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cambridge Cognition Holdings 5-Year EBITDA Growth Rate?

Cambridge Cognition Holdings LSE:COG 47 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates LSE:COG with a GF Score™ of 47/100 and a GF Value™ of £0.34 (Fairly Valued). The stock has 5 warning signs investors should review.

Cambridge Cognition Holdings's EBITDA per Share for the six months ended in Dec. 2025 was £-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cambridge Cognition Holdings was 48.70% per year. The lowest was -64.70% per year. And the median was 4.10% per year.


Cambridge Cognition Holdings  (LSE:COG) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Cambridge Cognition Holdings 5-Year EBITDA Growth Rate Related Terms


LSE:COG vs VEEV, BTSG, HQY: 5-Year EBITDA Growth Rate Comparison

For the Health Information Services subindustry, Cambridge Cognition Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambridge Cognition Holdings 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cambridge Cognition Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cambridge Cognition Holdings's 5-Year EBITDA Growth Rate falls into.


LSE:COG
47GF Score
Cambridge Cognition Holdings PLC LSE:COG
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambridge Cognition Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Cambridge Cognition Holdings (LSE:COG) has a 5-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cambridge Cognition Holdings and its competitors.
Is Cambridge Cognition Holdings' 5-Year EBITDA Growth Rate too high?
Cambridge Cognition Holdings' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Cambridge Cognition Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cambridge Cognition Holdings' 5-Year EBITDA Growth Rate compare to VEEV and BTSG?
Cambridge Cognition Holdings' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Cambridge Cognition Holdings and its competitors. Cambridge Cognition Holdings's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Cognition Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Cognition Holdings (LSE:COG) is currently considered Fairly Valued. The stock's GF Value™ is £0.34, compared to a current price of £0.33 — trading 2.9% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Cambridge Cognition Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Cambridge Cognition Holdings (LSE:COG), the current 5-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cambridge Cognition Holdings (LSE:COG) Overvalued in 2026?

Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued. The current stock price of £0.33 is trading 2.9% below its estimated GF Value™ of £0.34. GuruFocus considers Cambridge Cognition Holdings to be Fairly Valued.

Key valuation signals for LSE:COG:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: £0.34 vs. price of £0.33 (2.9% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the LSE:COG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cambridge Cognition Holdings Business Description

Other Exchanges 1M7:Germany
Address Tunbridge Lane, Tunbridge Court, Bottisham, Cambridge, GBR, CB25 9TU
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
47GF Score

Get the complete analysis for LSE:COG

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.33
Price
£0.34
GF Value